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BACKGROUND: Dose adjustment of non- vitamin K antagonist oral anticoagulants (NOACs) is indicated in some patients with 
atrial fibrillation (AF), based on selected patient factors or concomitant medications. We assessed the frequency of label 
adherence of NOAC dosing among AF patients and the associations between off- label NOAC dosing and clinical outcomes.
METHODS AND RESULTS: We evaluated 53 649 AF patients treated with an NOAC using Korean National Health Insurance 
Service database during the period from 2013 to 2016. NOAC doses were classified as either underdosed or overdosed, 
consistent with Korea Food and Drug Administration labeling. Cox proportional hazards regression was performed to inves-
tigate the effectiveness and safety outcomes including stroke or systemic embolism, major bleeding, and all- cause mortality. 
Overall, 16 757 NOAC- treated patients (31.2%) were underdosed, 4492 were overdosed (8.4%), and 32 400 (60.4%) were 
dosed appropriately according to drug labeling. Compared with patients with label adherence, those who were underdosed 
or overdosed were older (aged 71±8 and 75±7 years versus 70±9 years, respectively; P<0.001) and had higher CHA2DS2- 
VASc scores (4.6±1.7 and 5.3±1.7 versus 4.5±1.8, respectively; P<0.001). NOAC overdosing was associated with increased 
risk for stroke or systemic embolism (5.76 versus 4.03 events/100 patient- years, P<0.001), major bleeding (4.77 versus 2.94 
events/100 patient- years, P<0.001), and all- cause mortality (5.43 versus 3.05 events/100 patient- years, P<0.001) compared 
with label- adherent use.
CONCLUSIONS: In real- world practice, a significant proportion (almost 2 in 5) of AF patients received NOAC doses inconsistent 
with drug labeling. NOAC overdosing is associated with worse clinical outcomes in Asian AF patients.
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The prevalence of atrial fibrillation (AF) is rapidly increasing globally, especially in the Asian pop-ulation,1,2 and oral anticoagulation (OAC) is the 
principal management for stroke prevention in patients 
with AF.3,4 The efficacy and safety of the non- vitamin 
K antagonist oral anticoagulants (NOAC) have all been 
shown at least as effective and safe as warfarin in large 
randomized controlled trials.5–8
Dose adjustment of NOACs is indicated in some 
AF patients, based on selected patient factors such as 
renal function, age, body weight, or concomitant med-
ications.9 However, whether these dose recommenda-
tions are adhered to in community practice remains a 
major concern. In a study with ORBIT- AF II (Outcomes 
Registry for Better Informed Treatment of Atrial 
Fibrillation II) database,10 NOAC over- and underdosing 
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were shown to be associated with increased risk for 
adverse events. In addition, a previous study using a 
large US administrative database with about 15 000 AF 
patients revealed that the prescribed doses were often 
inconsistent with the renal dose recommendation by 
Food and Drug Administration labeling.11 In that study, 
inappropriate dose reduction was related to reduced 
effectiveness for stroke prevention without any safety 
benefit. Recently, we reported the real- world effective-
ness and safety of edoxaban in Korean AF patients in 
relationship to renal function.12 Interestingly, low- dose 
edoxaban had lower effectiveness for stroke preven-
tion compared with warfarin at higher levels of cre-
atinine clearance, which is called super normal renal 
function.
Therefore, in the current study, we sought to as-
sess the frequency of label adherence of NOAC dosing 
among Korean AF patients, and to analyze the asso-
ciations between off- label NOAC dosing and clinical 
outcomes in real- world clinical practice.
METHODS
Data Source
This study is based on the national health claims 
database established by the national health insur-
ance system (NHIS) of Republic of Korea.13,14 The 
NHIS is the single insurer managed by the Korean 
government, and the majority (97.1%) of the Korean 
population are mandatory subscribers, with the 
remaining 3% of the population being medical aid 
subjects. The NHIS database contains the informa-
tion of medical aid subjects, therefore it is based 
on the entire Korean population. All data and ma-
terials have been made publicly available at the 
National Health Insurance Sharing Service and can 
be accessed at (https://nhiss.nhis.or.kr/bd/ab/bda-
ba000eng.do).
The NHIS also provides regular health check- up 
programs for the public. Subscribers of the NHIS are 
recommended to undergo this check- up at least bi-
ennially, and it includes blood tests, chest X- ray ex-
aminations, physical examinations of the patients, 
and questionnaires on their medical history. Every 
population in the NHIS database was linked by the 
Korean social security numbers, and all social secu-
rity numbers were deleted after constructing the co-
hort by giving serial numbers to prevent leakage of 
personal information. This study was approved by the 
Institutional Review Board of Yonsei University Health 
System (4- 2016- 0179), and informed consent was 
waived.
Study Population
We identified a total of 866 363 patients with prevalent 
AF who were aged ≥18  years from January 1, 2013 
to December 31, 2016. AF was diagnosed using the 
International Classification of Diseases, Tenth Revision 
(ICD-10) codes, I48 (AF and atrial flutter), I48.0 (AF), 
and I48.1 (atrial flutter). Moreover, patients were diag-
nosed with AF only when it was a discharge diagnosis 
or confirmed more than twice in the outpatient depart-
ment to ensure diagnostic accuracy.15 The diagnosis of 
AF has previously been validated in the NHIS database 
with a positive predictive value of 94.1%.16–18 Definitions 
of other comorbidities are presented in Table S1. The 
following were exclusion criteria: (1) those with valvular 
AF (with a diagnosis of mitral stenosis [ICD-10: I05.0, 
I05.2, and I34.2] or prosthetic heart valves [ICD-10: 
Z95.2–Z95.4], and insurance claims for valve replace-
ment or valvuloplasty) (n=8646), (2) those who ever 
underwent catheter ablation (n=5607), (3) those ever 
diagnosed with end- stage renal disease (n=933), (4) no 
OAC or OAC use <30 days (n=717 946), (5) OAC use 
for acute coronary syndrome or deep vein thrombosis 




• The real-world label adherence of non-vitamin 
K antagonist oral anticoagulants (NOAC) dosing 
across all 4 NOACs and their clinical effects in 
Asian atrial fibrillation patients were investigated.
• Of those treated, only 60% of patients were 
dosed appropriately, with 30% of patients un-
derdosed in real-world practice.
What Are the Clinical Implications?
• NOAC overdosing was associated with in-
creased risk for adverse outcomes compared 
with label-adherent dosing.
• There was no safety benefit of underdos-
ing compared with the appropriate dosing of 
NOACs.
• Label adherence of NOAC dosing is important 
to improve the clinical outcomes in atrial fibrilla-
tion patients.
Nonstandard Abbreviations and Acronyms
AF atrial fibrillation
OAC oral anticoagulation
NOAC  non-vitamin K antagonist oral 
anticoagulants
NHIS  national health insurance system
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Among the 94  192 patients, patients without base-
line anthropometric and laboratory measurements for 
evaluation of compliance with labeled dosing were ex-
cluded (n=40 543). Finally, we identified 53 649 non- 
valvular AF patients in this study. We defined the date 
of the first oral anticoagulant prescription as the index 
date. The follow- up period was defined as from the 
index date until the first occurrence of any study out-
come or the end date of the study period (December 
31, 2016), whichever came first.
NOAC Dose Reduction Criteria and 
Dosing According to Label
A standard dose was defined, according to each 
NOAC, as dabigatran 150  mg twice daily, rivaroxa-
ban 20 mg once daily, apixaban 5 mg twice daily, and 
edoxaban 60  mg once daily. Approved dose reduc-
tion criteria were specific to each NOAC, according to 
the following patient characteristics: age, body weight, 
serum creatinine level at the patients’ enrollment, and 
concomitant medications. Creatinine clearance was 
calculated using the Cockcroft- Gault equation. The 
adherence with labeled dosing of each NOAC in each 
study patient was evaluated based on the Ministry of 
Food and Drug Safety labeling (Table S2). Patients 
were categorized into 3 groups based on NOAC dose 
and dose recommendation adherence: labeled use 
(n=32 400), underdosing (n=16 757), and overdosing 
(n=4492).
Study Outcomes
The primary study outcomes were stroke or systemic 
embolism, major bleeding, and death from any cause. 
Secondary outcomes were intracranial bleeding, gas-
trointestinal bleeding, and myocardial infarction. The 
clinical events that occurred after 1 week of quarantine 
periods after initial OAC prescription were counted as 
the study outcomes. The ICD codes for the study out-
comes are summarized in Table S3. Data on vital sta-
tus and date of death were reconfirmed, and the cause 
of death was determined from the National Population 
Registry of the Korea National Statistical Office with 
the use of a unique personal identification number, in 
which central registration of death was conducted on 
the basis of death certificates.19 This approach pro-
vides a complete event ascertainment.
Statistical Analysis
Continuous variables were presented as means and 
standard deviations. Comparison of continuous vari-
ables was performed using an independent t test or, in 
case of a non- normal distribution, the Mann–Whitney 
Figure 1. Flowchart of study population enrollment.
ACS indicates acute coronary syndrome; AF, atrial fibrillation; DVT, deep vein thrombosis; ESRD, end- stage renal disease; NOAC, non- 
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test. Categorical variables were represented with 
numbers and percentages using the Chi- square 
test of Fisher exact test. Incidence rates were es-
timated using the total number of study outcomes 
during the follow- up period divided by person- years 
at risk. The risk for clinical outcomes for study groups 
were obtained using survival analysis (Kaplan–Meier 
method and log- rank test for univariate analysis and 
Cox proportional hazards regression for multivari-
ate analysis). Cox proportional hazards regression 
was used to estimate the unadjusted and adjusted 
hazard ratio for the association between label ad-
herence of NOAC dosing and clinical outcomes. To 
control for confounding, we added age, sex, chronic 
kidney disease, dyslipidemia, and other risk factors 
included in CHA2DS2- VASc risk score factors (heart 
failure, hypertension, diabetes mellitus, stroke or 
transient ischemic attack, and vascular disease) to 
our multivariable models. Statistical significance was 
indicated by a P<0.05. All statistical analyses were 
performed using SAS version 9.4 (SAS Institute, 
Cary, NC) and SPSS version 23.0 statistical package 
(SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline Characteristics
Baseline characteristics of study population are 






(n=32 400) Overdosing (n=4492) P Value
Age, y 70.5±8.9 70.7±7.9 69.8±9.5 74.8±7.2 <0.001
Age <65 y 11 699 (21.8) 3086 (18.4) 8273 (25.5) 340 (7.6) <0.001
65≤ Age <75 y 22 763 (42.4) 7809 (46.6) 13 302 (41.1) 1652 (36.7) <0.001
Age ≥75 y 19 187 (35.8) 5862 (35.0) 10 825 (33.4) 2500 (55.7) <0.001
Men 32 350 (60.3) 10 230 (61.0) 20 016 (61.8) 2104 (46.8) <0.001
Comorbidities
Heart failure 32 845 (61.2) 10 257 (60.4) 19 574 (60.4) 3014 (67.1) <0.001
Hypertension 50 921 (96.3) 15 966 (95.3) 30 629 (94.5) 4326 (96.3) <0.001
Diabetes mellitus 16 952 (31.6) 5406 (32.3) 10 189 (31.4) 1357 (30.2) 0.021
Stroke or TIA 24 411 (45.5) 6968 (41.6) 15 096 (46.6) 2347 (52.2) <0.001
Vascular disease 15 443 (28.8) 4983 (29.7) 9045 (27.9) 1415 (31.5) <0.001
Previous MI 6285 (11.7) 2096 (12.5) 3625 (11.2) 564 (12.6) <0.001
PAD 10 935 (20.4) 3476 (20.7) 6443 (19.9) 1016 (22.6) <0.001
CKD 4354 (8.1) 1279 (7.6) 2613 (8.1) 462 (10.3) <0.001
Dyslipidemia 49 406 (92.1) 15 464 (92.3) 29 773 (91.9) 4169 (92.8) 0.055
CHA2DS2- VASc score 4.6±1.8 4.6±1.7 4.5±1.8 5.3±1.7 <0.001
NOAC type
Dabigatran 16 379 (30.5) 6428 (38.4) 8934 (27.6) 1017 (22.6) <0.001
Rivaroxaban 20 143 (37.5) 5426 (32.4) 12 332 (38.1) 2385 (53.1) <0.001
Apixaban 11 933 (22.2) 4002 (23.9) 7673 (23.7) 258 (5.7) <0.001
Edoxaban 5194 (9.7) 901 (5.4) 3461 (10.7) 832 (18.5) <0.001
Other medication use
Aspirin 8714 (16.2) 2916 (17.4) 5079 (15.7) 719 (16.0) <0.001
P2Y12 inhibitors 5005 (9.3) 1766 (10.5) 2792 (8.6) 447 (10.0) <0.001
ACEi/ARB 27 535 (51.3) 8537 (50.9) 16 714 (51.6) 2284 (50.8) 0.323
Beta- blockers 30 773 (57.4) 9698 (57.9) 18 589 (57.4) 2486 (55.3) 0.010
CCBs 9875 (18.4) 3173 (18.9) 5869 (18.1) 833 (18.5) 0.081
Digoxin 9766 (18.2) 3117 (18.6) 5617 (17.3) 1032 (23.0) <0.001
Diuretics 24 852 (46.3) 7866 (46.9) 14 632 (45.2) 2354 (52.4) <0.001
Statins 31 067 (57.9) 9560 (57.1) 18 917 (58.4) 2590 (57.7) 0.017
AAD (class Ic) 8730 (16.3) 2657 (15.9) 5590 (17.3) 483 (10.8) <0.001
AAD (class III) 5838 (10.9) 1697 (10.1) 3614 (11.2) 527 (10.9) <0.001
Values are mean±SD or n (%). AAD indicates anti- arrhythmic drug; ACEi, angiotensin- converting enzyme inhibitor; ARB, angiotensin II receptor blocker; 
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patients treated with NOACs (dabigatran 30.5%, ri-
varoxaban 37.5%, apixaban 22.2%, and edoxaban 
9.7%). The mean age was 70.5±8.9  years, 60.3% 
were men, and the mean CHA2DS2- VASc score 
was 4.6±1.8. Four thousand three hundred fifty- 
four (8.1%) patients had chronic kidney disease 
at baseline, and 16.2% and 9.3% of patients were 
prescribed concomitant aspirin and P2Y12 inhibi-
tors, respectively.
Label Adherence of NOAC Dosing
In the total study population, 31% NOAC- treated pa-
tients were underdosed, 8.4% were overdosed, and 
60% were dosed appropriately according to drug 
labeling. (Table) The overdosing group were older 
(74.8±7.2 years versus 69.8±9.5 years in labeled use 
group and 70.7±7.9  years in underdosing group), 
tended to be women (53.2% versus 38.2% in labeled 
use group and 39.0% in underdosing group), and 
had a higher CHA2DS2- VASc score (5.3±1.7 versus 
4.5±1.8 in labeled use group and 4.6±1.7 in under-
dosing group) than the other groups. Patients taking 
dabigatran or apixaban were prescribed with under-
dosing more frequently than those taking rivaroxaban 
or edoxaban, whereas patients taking rivaroxaban 
or edoxaban were more frequently prescribed with 
overdosing than those taking dabigatran or apixaban 
(Figure 2).
Clinical Outcomes According to Label 
Adherence
The cumulative incidence of stroke and systemic em-
bolism, major bleeding, intracranial bleeding, gastro-
intestinal bleeding, acute myocardial infarction and 
all- cause death is shown in Figure 3. There was a sig-
nificantly higher rate of stroke and systemic embolism, 
major bleeding, gastrointestinal bleeding, and all- cause 
death in patients with NOAC overdosing in comparison 
with labeled use or underdosing.
In reference with labeled use group, the adverse 
event in terms of stroke and systemic embolism 
were higher in overdosing group (5.76 versus 4.03 
events/100 patient- years; hazard ratio [HR], 1.45; 95% 
CI, 1.01–1.34; adjusted HR [aHR], 1.16; 95% CI, 1.01–
1.34) (Figure 4). Major bleeding was significantly higher 
in the overdosing group (4.77 versus 2.94 events/100 
patient- years; HR, 1.63; 95% CI, 1.39–1.90; aHR, 1.18; 
95% CI, 1.01–1.38). Mortality was also significantly 
higher in the overdosing group (5.43 versus 3.05 
events/100 patient- years; HR, 1.81; 95% CI, 1.56–2.09; 
aHR, 1.19; 95% CI, 1.02–1.38). The incidence rates 
of intracranial bleeding, gastrointestinal bleeding, or 
acute myocardial infarction were comparable between 
overdosing and labeled use group (Figure 4). On the 
other hand, underdosing was not associated with 
worse clinical outcomes in comparison with labeled 
NOAC use (Figure 5).
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The effectiveness and safety outcomes of 4 indi-
vidual NOACs in terms of over- /underdosing were 
also assessed (Figure S1). In reference with labeled 
use group, overdosing of dabigatran was associated 
with increasd risk of major bleeding (aHR, 1.39; 95% 
CI, 1.04–1.88) and gastrointestinal bleeding (aHR, 1.52; 
95% CI, 1.10–2.11). Overdosing of apixaban was asso-
ciated with increased risk of gastrointestinal bleeding 
(aHR, 1.83; 95% CI, 1.04–3.24) and all- cause death 
(aHR, 1.72; 95% CI, 1.10–1.88). In addition, underdos-
ing of rivaroxaban was associated with increasd risk of 
all- cause death (aHR, 1.37; 95% CI, 1.16–1.63) com-
pared with labeled use of rivaroxaban.
DISCUSSION
In the current study, we analyzed the label adherence 
of NOAC dosing across four NOACs and the associa-
tions between off- label NOAC dosing and clinical out-
comes in patients with AF in routine clinical practice. 
We found that off- label NOAC dosing was not uncom-
mon in the real- world practice: 31% NOAC- treated pa-
tients were underdosed, 8.4% were overdosed, and 
60% were dosed appropriately according to drug la-
beling. Compared with patients with label adherence, 
those who were underdosed or overdosed were older, 
more likely female, and had a higher CHA2DS2- VASc 
scores. According to the current analysis, underdos-
ing was not associated with worse clinical outcomes in 
comparison with labeled NOAC dosing, but there was 
no benefit in terms of safety either. However, NOAC 
overdosing was associated with increased risk for 
stroke or systemic embolism, major bleeding, and all- 
cause mortality compared with label- adherent dosing. 
These findings could give us meaningful messages of 
the real- world NOAC dosing patterns in patients with 
AF.
Label Adherence of NOAC Dosing in  
Real- World Practice
The appropriate dosing of NOACs for stroke preven-
tion in AF has become an important issue. Currently, 
there are several data on the prescribed doses of 
NOACs in clinical practice of stroke prevention in AF. In 
a small Australian analysis, inappropriate NOAC dos-
ing was identified in 34% and renal dysfunction was 
the primary driver of inappropriate dosing for those pa-
tients.20 In larger analysis, in the ORBIT- AF II registry, 
9.4% were underdosed, 3.4% were overdosed, and 
87% were dosed according to US labeling.10 Using a 
Figure 3. Cumulative incidence of clinical outcomes according to label adherence.
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large US claims database with 14  865 patients, Yao 
et al11 reported that 43.0% were potentially overdosed 
among the patients with a renal indication for dose 
reduction, and 13.3% were potentially underdosed 
among the patients with no renal indication for dose 
reduction. The use of low- dose NOAC is known to be 
more frequent among Asian AF patients. In Taiwanese 
nationwide data, 87% and 90% of the total study sub-
jects were shown to be taking low- dose rivaroxaban 
(10–15 mg once daily) and dabigatran (110 mg twice 
Figure 4. Incidence rates and hazard ratios of clinical outcomes in the overdosing group. Each HR was adjusted for age, 
sex, chronic kidney disease, dyslipidemia, and other risk factors included in CHA2DS2- VASc risk score factors (heart failure, 
hypertension, diabetes mellitus, stroke or transient ischemic attack, and vascular disease). 
HR indicates hazard ratio; ICH, intracranial bleeding; IR, incidence rate; MI, myocardial infarction; and S/SE, stroke or systemic 
embolism. *P value for adjusted HR.
Figure 5. Incidence rates and hazard ratios of clinical outcomes in the underdosing group.
Each HR was adjusted for age, sex, chronic kidney disease, dyslipidemia, and other risk factors included in CHA2DS2- VASc risk score 
factors (heart failure, hypertension, diabetes mellitus, stroke or transient ischemic attack, and vascular disease). HR indicates hazard 
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daily), respectively.21 In a recent Korean report using 
the Comparison Study of Drugs for Symptom Control 
and Complication Prevention of AF (CODE- AF) regis-
try,22 the label adherence of NOAC dosing was about 
60%, and more than one third of patients with NOAC 
prescription received an off- label reduced dose. 
However, neither studies reported the clinical outcome 
according to inappropriate NOAC dosing. In the pre-
sent study, we first reported the real- world label adher-
ence of NOAC dosing across all 4 NOACs and their 
clinical effects in Asian AF patients.
Clinical Implication of Label Adherence of 
NOAC Dosing
There are several studies that have reported clinical 
outcomes according to label adherence of NOAC dos-
ing. Previously we reported lower relative effectiveness 
for the prevention of thromboembolic events with low- 
dose edoxaban regimen (30 mg daily) compared with 
warfarin in patients with a creatinine clearance >95 mL/
min in real- world setting.12 In that study, a 30- mg dos-
age of edoxaban was used in 31% of patients with su-
pranormal renal clearance and ≈40% of patients were 
using lower doses of edoxaban inappropriately when 
analyzed based on body weight and creatinine clear-
ance criteria of label- recommended edoxaban dosing. 
In the ORBIT- AF II registry, NOAC over- and underdos-
ing were associated with increased risk for adverse 
events such as stroke or systemic embolism, myocar-
dial infarction, major bleeding, and all- cause mortality 
compared with the recommended dosing of NOACs.10 
Especially, inappropriate dose reduction of NOAC was 
associated with a reduced effectiveness for stroke 
prevention without any safety benefit.11 Recently, a 
meta- analysis of pivotal randomized controlled trials 
showed that NOACs had an improved benefit- harm 
profile compared with warfarin when appropriately 
dose- adjusted.23 Efficacy and safety of reduced- dose 
NOACs compared with warfarin in patients eligible for 
reduced- dose NOACs were consistent with those of 
full- dose NOACs relative to warfarin in those eligible 
for full- dose NOACs. In our current study, the adverse 
clinical consequence was higher in the overdosing 
group compared with the on- label dosing group, and 
there was no safety benefit of underdosing compared 
with the appropriate dosing of NOACs. Based on the 
results so far, label adherence of NOAC dosing is im-
portant to improve the clinical outcomes in AF patients, 
and further investigation is needed to assess the opti-
mal dosing of NOACs in the Asian AF population.
Study Limitations
There are several limitations in the present study. First, 
we classified NOAC dosing groups based on patients’ 
baseline clinical characteristics, there is the possibility 
that other confounding factors and changes in patient 
status during the follow- up period may have influenced 
the physician’s prescription decisions. Especially 
changes in NOAC dosing during the follow- up period 
was not captured in the present analysis, which may in 
turn affect the findings of the study. Second, the poor 
clinical outcome of patients in overdosing group might 
be affected by their older age and higher prevalence of 
comorbidities, although the NOAC dosing label already 
reflects factors such as age, body weight, and kidney 
function. However, because we thought that differences 
in base characteristics and comorbidities such as patient 
age or renal function were important factors in determin-
ing appropriate NOAC dosing, we present the analysis 
without matching among groups to show the results 
as they are in the real world practice setting. Finally, the 
present nationwide study only enrolled the entire Korean 
population, whether the results can be extrapolated to 
other populations remains uncertain. Despite these limi-
tations, our findings reflect the real- world practice pat-
tern of NOAC dosing in Asian AF patients and the clinical 
consequences of label adherence of NOAC dosing.
CONCLUSIONS
In routine clinical practice, a significant proportion of AF 
patients received NOAC doses inconsistent with drug 
labeling. NOAC overdosing is associated with increased 
risk for stroke or systemic embolism, major bleeding, 
and all- cause mortality in Asian AF patients. NOAC 
underdosing was not significantly associated with in-
creased risk of stroke, but there was no safety benefit in 
comparison with label- adhered NOAC dosing.
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Table S1. Definitions and ICD-10 codes used for defining the comorbidities. 
 
Comorbidities Definitions ICD-10 codes or conditions 
Heart failure Defined from diagnosis* ICD10: I11.0, I50, I97.1 
Diabetes mellitus 
Defined from diagnosis* plus 
treatment 
ICD10: E10, E11, E12, E13, E14 
Treatment: all kinds of oral antidiabetics 
and insulin. 
Ischemic stroke Defined from diagnosis* ICD10: I63, I64 
Hemorrhagic stroke Defined from diagnosis* ICD10: I60, I61, I62 
Myocardial infarction Defined from diagnosis* ICD10: I21, I22, I25.2 
Peripheral arterial disease Defined from diagnosis* ICD10: I70.0, I70.1, I70.2, I70.8, I70.9 
Chronic kidney disease 
 
Defined from eGFR (if 
laboratory value was not 
available, diagnosis code was 
used) 
eGFR <45 mL/min per 1.73 m2 (ICD10: 
N18, N19) 
Dyslipidemia Defined from diagnosis* E78 
 
*To ensure accuracy, comorbidities were established based on one inpatient or two outpatient records 
of ICD-10 codes in the database. 












Table S2. The dose-adjustment criteria for the NOACs under the Korean labeling and the criteria 
used in the phase 3 RCT. 
 Dabigatran Rivaroxaban  Apixaban Edoxaban 
Standard dose 150 mg twice 
daily  




 15mg once daily  
if CrCl 30-49 
mL/min 
2.5 mg twice 
daily, if at least 2 
of age ≥80 years, 
body weight 
≤60kg or serum 
creatinine level 
≥1.5 mg/dL  
30 mg once daily, 
if any of the 
following: CrCl of 
30-50mL/min, 
body weight ≤60 
kg, concomitant 
use of verapamil 





110 mg twice 
daily, if any of the 
following: CrCl 
30-50 mL/min, 
age ≥75 years 
15mg once daily 
if CrCl 15-49 
mL/min 
2.5 mg twice 
daily, if at least 2 
of age ≥80 years, 
body weight ≤60 
kg or serum 
creatinine level 
≥1.5 mg/dL 
2.5 mg twice 
daily, if CrCl 15-
29 mL/min 
30 mg once daily, 
if any of the 
following: CrCl of 
15-50mL/min, 
















Table S3. Definitions and ICD-10 codes used for defining the outcomes. 
Outcomes Definitions ICD-10 codes 
Ischemic stroke Defined from diagnosis of ischemic stroke 
with concomitant imaging studies of the 
brain or related death 
I63, I64 
  
Systemic embolism Defined from admission diagnosis or related 
death 




Defined from admission diagnosis of ICH 
with concomitant imaging studies of the 




Defined from admission diagnosis or related 
death 
K25-28 (subcodes 0-2 and 4-6 
only), K92.0, K92.1, K92.2, 
K62.5, I85.0, I98.3 
Major bleeding ICH, gastrointestinal bleeding, or anemia 
caused by bleeding 
I60-I62, K25-28 (subcodes 0-2 
and 4-6 only), K92.0, K92.1, 
K92.2, K62.5, I85.0, I98.3, D62 
Acute myocardial 
infarction 
Defined from admission diagnosis of AMI 
with concomitant use of dual antiplatelet 




Defined from admission diagnosis (including 
only main and first sub-diagnosis) 
I11.0, I50, I97.1 
 
*To ensure accuracy, comorbidities were established based on one inpatient or two outpatient records 
of ICD-10 codes in the database. 











Figure S1. The effectiveness and safety outcomes of 4 individual NOACs in terms of over-/under-
dosing. 
 
HR, hazard ratio; S/SE, stroke or systemic embolism; ICH, intracranial bleeding; GI, gastrointestinal; 
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